Secondary Prevention With Bezafibrate Therapy for the Treatment of Dyslipidemia. An Extended Follow-Up of the BIP Trial

Journal of the American College of Cardiology

Volumn 51, Issue 4, 2008, Pages 459-465

  Goldenberg, Ilan ^a   Benderly, Michal ^a   Goldbourt, Uri ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; PLACEBO;

ACUTE HEART INFARCTION; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DYSLIPIDEMIA; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION PREVENTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SECONDARY PREVENTION; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; ANTILIPEMIC AGENTS; BEZAFIBRATE; CHOLESTEROL; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; TREATMENT OUTCOME;

EID: 38349138583     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2007.09.048     Document Type: Article

References (11)

1. Goldbourt U., Behar S., Reicher-Reiss H., et al., Bezafibrate Infarction Prevention Study Group. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinical manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol 71 (1993) 909-915
2. BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 102 (2000) 21-27
3. Rubins H.B., Robins S.J., Collins D., et al., Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341 (1999) 410-418
4. Frick M.H., Elo O., Haapa K., et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 317 (1987) 1237-1245
5. D'Agostino Jr. R.B. Propensity score methods for bias reduction in the comparison of a treatment to a nonrandomized control group. Stat Med 17 (1998) 2265-2281
6. Baseline characteristics of patients participating in the Bezafibrate Infarction Prevention (BIP) study. Eur Heart J 19 (1998) H42-H47
7. Rubins H.B., Robins S.J., Collins D., et al. Diabetes, plasma insulin and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 162 (2002) 2597-2604
8. Tenenbaum A., Motro M., Fisman E., et al. Bezafibrate for the secondary prevention of myocardial infarction in patients with the metabolic syndrome. Arch Intern Med 165 (2005) 1154-1160
9. Robins S.J., Rubins H.B., Faas F.H., et al. Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT). Diabetes Care 26 (2003) 1513-1517
10. Robins S.J. Lipid therapy for cardiovascular disease with insulin resistance, diabetes, or the metabolic syndrome. Curr Cardiol Rep 7 (2005) 457-464
11. Toth P.P. High-density lipoprotein and cardiovascular risk. Circulation 109 (2004) 1809-1812